ATM and gallbladder cancer: A patient with advanced gallbladder cancer had a tumor with an ATM mutation and 100% ATM IHC loss; this patient achieved a best response of RECISTv1.1 SD but discontinued trial after 11 weeks for early clinical disease progression.